☆ 4.7 Article

Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

ANNALS OF ONCOLOGY (2013)

期刊

ANNALS OF ONCOLOGY

卷 24, 期 -, 页码 125-132

出版社

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdt304

关键词

-

类别

Oncology

资金

Sanofi
Bayer Health Care
Orion Pharma
Merck

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer

R. Kanesvaran, E. Castro, A. Wong, K. Fizazi, M. L. K. Chua, Y. Zhu, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, K. Prabhash, Q. Zou, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: To accommodate the specific requirements of prostate cancer treatment in Asia, a special meeting was convened by ESMO and SSO to revise the guidelines published in 2020. These guidelines represent the consensus opinions of prostate cancer treatment experts from Asian countries and aim to provide optimization and harmonization recommendations for the management of prostate cancer patients across different regions in Asia.

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

T. Yoshino, G. Argiles, E. Oki, E. Martinelli, H. Taniguchi, D. Arnold, Mishima, Y. Li, B. K. Smruti, J. B. Ahn, I. Faud, C. E. Chee, K. -h. Yeh, P. -c. Lin, C. Chua, H. H. Hasbullah, M. A. Lee, A. Sharma, Y. Sun, G. Curigliano, H. Bando, F. Lordick, T. Yamanaka, J. Tabernero, E. Baba, A. Cervantes, A. Ohtsu, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO 2020 guidelines for localised colon cancer were adapted to account for ethnic differences in Asian patients during a special virtual meeting convened by ESMO and JSMO in March 2021. These guidelines represent the consensus opinions of experts from various oncological societies in Asia, and the voting was based on scientific evidence.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

T. Yoshino, A. Cervantes, H. Bando, E. Martinelli, E. Oki, R. -H. Xu, N. A. Mulansari, K. Govind Babu, M. A. Lee, C. K. Tan, G. Cornelio, D. Q. Chong, L. -T. Chen, S. Tanasanvimon, N. Prasongsook, K. -H. Yeh, C. Chua, M. D. Sacdalan, W. J. Sow (Jenson), S. T. Kim, R. T. Chacko, R. A. Syaiful, S. Z. Zhang, G. Curigliano, S. Mishima, Y. Nakamura, H. Ebi, Y. Sunakawa, M. Takahashi, E. Baba, S. Peters, C. Ishioka, G. Pentheroudakis

Summary: The ESMO Guidelines for metastatic colorectal cancer (mCRC) were adapted to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for Asian patients. The guidelines were developed by a panel of experts from Asian oncological societies, based on scientific evidence and independent of treatment practices and reimbursement decisions. The aim is to optimize and harmonize the management of mCRC across Asia, considering the differences in screening practices, molecular profiling, and drug approvals and reimbursement strategies.

ESMO OPEN (2023)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

R. Kanesvaran, C. Porta, A. Wong, T. Powles, Q. S. Ng, M. Schmidinger, D. Ye, H. Malhotra, Y. Miura, J. L. Lee, F. L. T. Chong, Y-S Pu, C-C Yen, M. Saad, H. J. Lee, H. Kitamura, G. S. Bhattacharyya, G. Curigliano, E. Poon, S. P. Choo, S. Peters, E. Lim, T. Yoshino, G. Pentheroudakis

Summary: The ESMO and SSO held a special virtual guidelines meeting in May 2021 to adapt the 2019 guidelines for renal cell carcinoma treatment to account for ethnic differences in Asian patients. Expert opinions from oncological societies in China, India, Japan, Korea, Malaysia, Singapore, and Taiwan were considered based on scientific evidence independent of current treatment practices and drug access restrictions in Asian countries.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

S. J. Strauss, A. M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J. Y. Blay, S. Bolle, S. Bonvalot, I Boukovinas, J. V. M. G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Alava, A. P. Dei Tos, X. Garcia Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A. B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R. L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D. A. Krakorova, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A. B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M. A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A. A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schoffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M. A. J. van de Sande, W. T. A. van der Graaf, W. J. van Houdt, T. Frebourg, R. Ladenstein, P. G. Casali, S. Stacchiotti

Summary: The paragraph lists the names of various researchers, possibly in the author list of a research paper.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Urology & Nephrology

Guideline of guidelines: follow-up after orchidectomy for clinical stage 1 testicular cancer

Julian Chavarriaga, Adam Bobrowski, Robert J. Hamilton

Summary: This article reviews and compares international guidelines and surveillance protocols for the diagnosis, management, and follow-up of clinical stage 1 (CS1) testicular cancer. The authors analyzed 46 articles on proposed follow-up strategies and six clinical practice guidelines, finding considerable variability and differences in recommended follow-up intensity.

BJU INTERNATIONAL (2023)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L. -Y. Wu, W. Rajabto, K. Harano, S. -h. Hong, R. A. Malik, H. Strebel, I. M. Aggarwal, C. -H. Lai, T. Dejthevaporn, S. Tangjitgamol, W. F. Cheng, W. Y. Chay, D. Benavides, N. M. Hashim, Y. W. Moon, M. Yunokawa, T. D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis

Summary: The European Society for Medical Oncology (ESMO) published the most recent version of their guidelines for endometrial cancer in 2022. In order to account for variations in endometrial cancer management in Asia, a virtual meeting was held in July 2022 to adapt the ESMO guidelines. The guidelines represent the consensus opinion of Asian experts from various oncological societies. The aim is to provide guidance for the management of endometrial cancer in different regions of Asia, considering variations in clinical presentation, diagnostic practices, and access to treatment options.

ESMO OPEN (2023)

添加到收藏夹

Article Oncology

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

B. Keam, J-P Machiels, H. R. Kim, L. Licitra, W. Golusinski, V Gregoire, Y. G. Lee, C. Belka, Y. Guo, S. J. Rajappa, M. Tahara, M. Azrif, M. K. Ang, M-H Yang, C-H Wang, Q. S. Ng, W. I. Wan Zamaniah, N. Kiyota, S. Babu, K. Yang, G. Curigliano, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis

Summary: ESMO and KSMO convened a special virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider potential ethnic differences in Asian patients' treatment of SCCs of the head and neck. These guidelines represent consensus opinions from experts across Asia and provide expert recommendations for the diagnosis, treatment, and management of patients with SCC of the oral cavity, larynx, oropharynx, and hypopharynx.

ESMO OPEN (2021)

添加到收藏夹

Review Andrology

miRNAs for testicular germ cell tumours: Contemporary indications for diagnosis, surveillance and follow-up

Julian Chavarriaga, Robert J. Hamilton

Summary: Clinicians caring for patients with testicular germ cell tumour (TGCTs) are faced with clinical dilemmas and the available biomarkers lack sufficient sensitivity and specificity. Hence, a sensitive and specific biomarker is desperately needed. Serum or plasma miRNA, especially miR-371a-3p, shows great promise in distinguishing the presence of TGCT and may be a breakthrough for this disease.

ANDROLOGY (2023)

添加到收藏夹

Article Oncology

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

S. -A. Im, A. Gennari, Y. H. Park, J. H. Kim, Z. -F. Jiang, S. Gupta, T. H. Fadjari, K. Tamura, M. Y. Mastura, M. L. T. Abesamis-Tiambeng, E. H. Lim, C. -H. Lin, A. Sookprasert, N. Parinyanitikul, L. -M. Tseng, S. -C. Lee, P. Caguioa, M. Singh, Y. Naito, R. A. Hukom, B. K. Smruti, S. -S. Wang, S. B. Kim, K. -H. Lee, H. K. Ahn, S. Peters, T. W. Kim, T. Yoshino, G. Pentheroudakis, G. Curigliano, N. Harbeck

Summary: The most recent version of the ESMO Clinical Practice Guidelines for metastatic breast cancer was published in 2021. In 2022, a special hybrid guidelines meeting was held to adapt these guidelines to the Asian context, with input from Asian oncology societies. The aim is to provide harmonized management of MBC patients across Asia.

ESMO OPEN (2023)

添加到收藏夹

Review Oncology

Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)

Jose Alejandro Perez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla, Claudia Valverde, Josep Isern Verdum, Enrique de Alava, Mar Galera Lopez, Gloria Marquina, Ana Sebio

Summary: Uterine sarcomas are rare and diverse, making diagnosis, surgical management, and systemic treatment challenging; treatment decisions should involve a multidisciplinary tumor board; evidence is limited, often based on case series or clinical trials including these tumors with other soft tissue sarcomas. These guidelines summarize the relevant evidence on the diagnosis, staging, pathological disparities, surgical management, systemic treatment, and follow-up of uterine sarcomas.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

添加到收藏夹

Article Urology & Nephrology

Clinical characteristics, treatment patterns and relapse in patients with clinical stage IS testicular cancer

Maximilian Peter Brandt, C. Ruf, K. P. Dieckmann, I Syring, C. Ruckes, T. Nestler, H. U. Schmelz, R. Dotzauer, A. Hiester, P. Albers, D. Nettersheim, C. Bolenz, S. H. Loosen, A. Heidenreich, D. Pfister, A. Haferkamp, F. Zengerling, P. Paffenholz

Summary: In this study, the clinical characteristics and oncological outcomes of patients with CSIS were assessed. Data from five tertiary referring centers in Germany were analyzed, identifying 43 out of 2616 TGCT patients as CSIS. The correct classification of cCSIS was crucial in guiding treatment and achieving a 5-year relapse-free survival rate of 88.9%.

WORLD JOURNAL OF UROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Non-invasive diagnosis and follow-up of autoimmune hepatitis

Sara Lemoinne, Alexandra Heurgue, Charlotte Bouzbib, Bertrand Hanslik, Jerome Gournay, Eric Nguyen-Khac, Christophe Bureau, Victor de Ledinghen, Nathalie Ganne-Carrie, Marc Bourliere

Summary: Autoimmune hepatitis (AIH) is a liver disease characterized by necro-inflammatory lesions of hepatocytes, specific autoantibodies, and response to corticosteroid treatment. The diagnosis is based on a combination of clinical, biological, immunological, and histological findings, after excluding other causes of liver disease. Non-invasive tests can be used at different steps in the management of AIH for diagnosis and follow-up.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

Tetsuhide Ito, Toshihiko Masui, Izumi Komoto, Ryuichiro Doi, Robert Y. Osamura, Akihiro Sakurai, Masafumi Ikeda, Koji Takano, Hisato Igarashi, Akira Shimatsu, Kazuhiko Nakamura, Yuji Nakamoto, Susumu Hijioka, Koji Morita, Yuichi Ishikawa, Nobuyuki Ohike, Atsuko Kasajima, Ryoji Kushima, Motohiro Kojima, Hironobu Sasano, Satoshi Hirano, Nobumasa Mizuno, Taku Aoki, Takeshi Aoki, Takao Ohtsuka, Tomoyuki Okumura, Yasutoshi Kimura, Atsushi Kudo, Tsuyoshi Konishi, Ippei Matsumoto, Noritoshi Kobayashi, Nao Fujimori, Yoshitaka Honma, Chigusa Morizane, Shinya Uchino, Kiyomi Horiuchi, Masanori Yamasaki, Jun Matsubayashi, Yuichi Sato, Masau Sekiguchi, Shinichi Abe, Takuji Okusaka, Mitsuhiro Kida, Wataru Kimura, Masao Tanaka, Yoshiyuki Majima, Robert T. Jensen, Koichi Hirata, Masayuki Imamura, Shinji Uemoto

Summary: Neuroendocrine neoplasms (NENs) are rare tumors with diverse clinical manifestations. Accurate pathological classification and determination of tumor characteristics are crucial for selecting appropriate treatment strategies. The revised Clinical Practice Guidelines for Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) provide comprehensive directions for the management of NENs, incorporating new evidence and updated concepts.

JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Otorhinolaryngology

The challenging diagnosis and follow-up of skull base osteomyelitis in clinical practice

Alice B. Auinger, Valerie Dahm, Isabella Stanisz, Ursula Schwarz-Nemec, Christoph Arnoldner

Summary: The management of skull base osteomyelitis requires a combination of different imaging modalities for diagnosis and follow-up. MRI is preferable for follow-up as changes can be detected more readily, while nuclear medicine imaging is most effective in assessing disease activity.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2021)

添加到收藏夹

Article Oncology

Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials

Jun Yin, Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery DeGramont, Eric Van Cutsem, Julien Taieb, Steven R. Alberts, Norman Wolmark, Hans-Joachim Schmoll, Leonard B. Saltz, Thomas J. George, Richard R. M. Goldberg, Rachel Kerr, Sara Lonardi, Takayuki Yoshino, Greg Yothers, Axel Grothey, Thierry Andre, Qian Shi

Summary: The study suggests that 3-year disease-free survival (DFS) can effectively replace 5-year overall survival (OS) as an endpoint in adjuvant chemotherapy colon cancer trials. Data shows that the association between DFS and OS strengthens as the follow-up duration of OS increases.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Oncology

Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours

Christian D. Fankhauser, Ailsa J. Christiansen, Christian Rothermundt, Richard Cathomas, Marian S. Wettstein, Nico C. Grossmann, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Joerg Beyer, Thomas Hermanns

Summary: MiR-371a-3p can detect recurrence during active surveillance of stage I GCT earlier and more reliably than standard follow-up investigations.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of bevacizumab-based treatment in early-onset treatment-naive metastatic colorectal cancer patients: An ARCAD database analysis

Zhaohui Jin, Jesse G. Dixon, Joleen M. Hubbard, Cathy Eng, Christopher Hanyoung Lieu, Jack Fiskum, Leonard B. Saltz, Herbert I. Hurwitz, Alan P. Venook, Hans-Joachim Schmoll, Charles S. Fuchs, J. Randolph Randolph Hecht, Chiara Cremolini, Eduardo Diaz-Rubio, Cornelis J. A. Punt, Niall C. Tebbutt, Volker Heinemann, Takayuki Yoshino, Aimery De Gramont, Qian Shi

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology

Richard M. Goldberg, Richard Adams, Marc Buyse, Cathy Eng, Axel Grothey, Thierry Andre, Alberto F. Sobrero, Stuart M. Lichtman, Al B. Benson, Cornelis J. A. Punt, Tim Maughan, Tomasz Burzykowski, Dirkje Sommeijer, Everardo D. Saad, Qian Shi, Elisabeth Coart, Benoist Chibaudel, Miriam Koopman, Hans-Joachim Schmoll, Takayuki Yoshino, Julien Taieb, Niall C. Tebbutt, John Zalcberg, Josep Tabernero, Eric Van Cutsem, Alastair Matheson, Aimery de Gramont

Summary: Meta-analysis based on individual participant data is a powerful method for synthesizing evidence in clinical cancer research. The ARCAD database is a leader in using this methodology for methodological research, providing valuable insights into endpoint selection and clinical response assessment.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data

Sanna Iivanainen, Jussi Ekstrom, Henri Virtanen, Vesa V. Kataja, Jussi P. Koivunen

Summary: In this study, a machine learning-based model was built to predict the overall response rate (ORR) of ICIs in cancer patients. The model utilized patient-reported symptom data and other clinical data as inputs, and achieved promising performance in predicting ORR with a high accuracy, AUC, F1 score, and MCC. It was found that itching and fatigue were the two most important symptoms for predicting ORR.

APPLIED SCIENCES-BASEL (2022)

添加到收藏夹

Article Cell Biology

Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours

Joao Lobo, Angelo Rodrigues, Rui Henrique, Ailsa Christiansen, Jorg Beyer, Holger Moch, Peter Karl Bode

Summary: Somatic malignant transformation (SMT) arising in germ cell tumours (GCTs) is a rare but clinically relevant event. This study revisited two consecutive case series of GCTs and found a wide range of challenging morphologies in SMT. SMT can be confirmed by Fluorescence in situ Hybridization (FISH) and Next Generation Sequencing (NGS), and treatment recommendations based on molecular profiles may improve patient outcomes.

HISTOPATHOLOGY (2022)

添加到收藏夹

Article Oncology

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Andres J. M. Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P. Fox, Elisabeth Schorb, Claudia Celico, Monica Falautano, Alessandro Nonis, Paul La Rosee, Mascia Binder, Alberto Fabbri, Fiorella Ilariucci, Mauro Krampera, Alexander Roth, Claire Hemmaway, Peter W. Johnson, Kim M. Linton, Tobias Pukrop, Jettes Sonderskov Gorlov, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jense Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Manuela Zanni, Stefan W. Krause, Hans J. Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Lorenz Thurner, Giuseppina Cabras, Elsa Pennese, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jurgen Finke, Antonella Ferranti, Kelly Cozens, Elvira Burger, Nicoletta Ielmini, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus

Summary: This study reported the results of a trial involving 219 HIV-negative adults with primary CNS lymphoma (PCNSL). The results showed that MATRix significantly improves outcome in patients with PCNSL, with a long-term overall survival rate of 21%-56%. Addition of rituximab benefits patients, and the efficacy of whole-brain irradiation and autologous transplantation is comparable. Salvage therapy was ineffective. Importantly, MATRix and ASCT did not increase non-relapse mortality or second tumor incidence, and the side effects differed between WBRT and ASCT.

LEUKEMIA (2022)

添加到收藏夹

Meeting Abstract Oncology

Clinical classification-based evaluation of adjuvant therapy with oxaliplatin in stage II colon cancer

B. Chibaudel, M. Raeisi, T. Andre, G. Yothers, H. Schmoll, J. Bachet, R. Cohen, N. Wolmark, T. Yoshino, R. Goldberg, R. Kerr, S. Lonardi, T. George, E. Shacham-Shmueli, L. Sharara, Q. Shi, A. de Gramont

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Optimizing ipilimumab in RCC: Results from SAKK 07/17 (CM-980) nivolumab (N) plus ipilimumab (Ipi) in mRCC

F. Stenner-Liewen, R. Cathomas, C. A. Rothermundt, J. Beyer, N. Mach, D. Zihler, A. A. Erdmann, M. Kueng, D. Dietrich, J. Glaus Garzon, A. Lorch, D. R. Berthold, H. Laubli

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database

S. Gillessen, J. Lauritsen, N. Sauve, A. Tryakin, D. M. Jiang, R. A. Huddart, D. Y. C. Heng, A. Terbuch, E. Winquist, M. Chovanec, M. Hentrich, C. D. Fankhauser, J. Shamash, X. Garcia Del Muro, D. J. Vaughn, A. Heidenreich, A. Jandari, L. Collette, J. Beyer, K. G. Daugaard

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer

J. Tabernero, A. Grothey, D. Arnold, A. de Gramont, M. Ducreux, P. O'Dwyer, A. Tahiri, F. Gilberg, N. Irahara, H-J Schmoll, E. Van Cutsem

Summary: The addition of atezolizumab to FP/bevacizumab as first-line maintenance treatment after FOLFOX thorn bevacizumab induction did not improve efficacy outcomes for patients with BRAF wild-type metastatic colorectal cancer (mCRC).

ESMO OPEN (2022)

添加到收藏夹

Article Oncology

Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence

Ailsa J. Christiansen, Joao Lobo, Christian D. Fankhauser, Christian Rothermundt, Richard Cathomas, Aashil A. Batavia, Josias B. Grogg, Arnoud J. Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Joerg Beyer, Thomas Hermanns

Summary: Serum miR-371a-3p can identify disease recurrence in TGCT patients, but the lack of consensus regarding optimal methodologies hinders its clinical implementation. Pre-amplification increases sensitivity but may lead to more false positives. Further standardized studies are needed before routine clinical use.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials

C. Gallois, Q. Shi, J. Meyers, T. Andre, T. J. Iveson, A. F. Sobrero, S. Alberts, A. de Gramont, J. Meyerhardt, A. F. Shields, T. Georges, H. J. E-V. Schmoll, I. Souglakos, R. Kerr, S. Lonardi, G. Yothers, T. Yoshino, R. Goldberg, J. Taieb, D. Papamichael

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Oncology

Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.

Romain Cohen, Morteza Raeisi, Greg Yothers, Hans-Joachim Schmoll, Daniel G. Haller, Jean-Baptiste Bachet, Benoist Chibaudel, Norman Wolmark, Takayuki Yoshino, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Thomas J. George, Einat Shacham Shmueli, Lama Sharara, Thierry Andre, Qian Shi, Aimery De Gramont

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First-and Second-Line Clinical Trials

Nadine J. McCleary, William S. Harmsen, Ellana Haakenstad, James M. Cleary, Jeffrey A. Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F. Sobrero, Eric Van Cutsem, Richard M. Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B. Saltz, Bruce J. Giantonio, Dirk Arnold, Mace L. Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C. Pitot, Paulo M. Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M. Lichtman

Summary: This study evaluated the time to progression and survival outcomes of second-line therapy for metastatic colorectal cancer in older adults aged 70 years and older compared with younger adults. It found that older adults were less likely to receive second-line therapy, but there was no statistically significant difference in survival outcomes between older and younger adults following second-line therapy.

JNCI CANCER SPECTRUM (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.